Is Juno Therapeutics Stock Still a Strong Buy?

Is Juno Therapeutics Stock Still a Strong Buy?

Shares of the clinical-stage biotech Juno Therapeutics (NASDAQ: JUNO) rose by a healthy 22% last month, according to S&P Global Market Intelligence. The drugmaker's shares seemed to get a lift from two different catalysts during the month.

First off, the company provided yet another positive clinical update for its lead cell therapy, JCAR017, in relapsed and refractory aggressive B cell non-Hodgkin lymphoma (NHL) at the 2017 International Conference on Malignant Lymphoma in Lugano, Switzerland.

Image source: Getty Images.

Continue reading

Source: Fool.com